What does a low Maximum Amplitude (MA) on Thromboelastography (TEG) indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What Does Low MA Mean on TEG?

A low Maximum Amplitude (MA) on thromboelastography indicates decreased clot strength, primarily reflecting thrombocytopenia, platelet dysfunction, or fibrinogen deficiency. 1, 2

Understanding Low MA

  • Maximum Amplitude (MA) represents the maximum strength of the clot and primarily reflects platelet function and fibrinogen concentration. 1, 2

  • Normal MA values typically range from 50-70 mm, with values <50 mm indicating significant clot strength impairment. 2

  • Decreased MA suggests thrombocytopenia, platelet dysfunction, or fibrinogen deficiency. 1, 2

Relative Contributions to Clot Strength

  • Fibrinogen contributes approximately 30-45% to overall clot strength (MA), while platelets contribute 55-70%. 3, 4, 5

  • The fibrinogen contribution to clot strength has a direct linear relationship with fibrinogen level (R = 0.83), meaning lower fibrinogen levels result in proportionally lower fibrinogen contribution. 4

  • Platelet count has only a moderate correlation to clot strength (R = 0.51), whereas functional fibrinogen has a stronger correlation (R = 0.80). 4

Clinical Significance

  • Low MA is associated with increased bleeding risk and higher transfusion requirements. 5

  • Coagulopathic patients have significantly lower fibrinogen contribution to MA compared to non-coagulopathic patients (24.7% vs. 31.2%). 5

  • Patients requiring plasma transfusion have significantly lower fibrinogen contribution to MA (26.6% vs. 30.6%). 5

  • Higher fibrinogen contribution to clot strength is predictive of reduced mortality (hazard ratio 0.815). 5

Diagnostic Approach

  • Use functional fibrinogen TEG to differentiate between fibrinogen and platelet contributions to the low MA. 2, 4

  • If functional fibrinogen TEG is unavailable, check conventional laboratory tests including platelet count and fibrinogen level to guide therapy. 2

  • A strong correlation exists between functional fibrinogen TEG and von Clauss fibrinogen levels (R = 0.87). 4

Treatment Algorithm

For Fibrinogen Deficiency:

  • If fibrinogen level <1.5-2.0 g/L or functional fibrinogen TEG shows decreased contribution, administer fibrinogen concentrate (first choice) at 25-50 mg/kg. 2

  • Alternative: administer 2 pools of cryoprecipitate (equivalent to 4g fibrinogen replacement). 2

  • Target fibrinogen level of at least 1.5-2.0 g/L in bleeding patients, with higher targets (>2.0 g/L) in obstetric hemorrhage. 2

For Thrombocytopenia or Platelet Dysfunction:

  • If platelet count <50,000/mm³ or there is evidence of platelet dysfunction, administer platelet transfusion (1 adult dose). 2

  • Target platelet count >50,000/mm³ for most bleeding scenarios. 2

  • Consider higher platelet count targets (>100,000/mm³) for patients with traumatic brain injury or requiring neurosurgery. 2

Monitoring Response

  • Repeat TEG 15-30 minutes after intervention to assess response. 2

  • Target MA normalization (typically >50 mm). 2

Important Pitfalls and Caveats

  • Standard TEG is insensitive to antiplatelet agents and cannot reliably detect platelet dysfunction. 1, 2, 6

  • Anemia can paradoxically show hypercoagulable TEG results due to decreased blood viscosity, potentially masking coagulopathy. 1, 2

  • Do not rely solely on conventional coagulation tests (PT, aPTT) as they may not correlate well with TEG parameters. 2

  • TEG shows high coefficients of variance (7.1-39.9% for TEG parameters), so results should be interpreted with caution and in clinical context. 1

  • Results vary between devices and are not interchangeable between TEG and ROTEM systems. 1

  • TEG cannot detect von Willebrand disease or disorders affecting endothelial adherence. 1

Special Considerations in Obstetrics

  • In pregnancy, baseline MA values are elevated due to physiologic hypercoagulability, so pregnancy-specific reference ranges must be used. 3

  • Abnormal TEG MA correlated with prolonged bleeding time, making TEG useful for assessing thrombocytopenia in pregnancy. 3

  • Low MA (≤54.2 mm) in pregnancy is associated with significantly high odds ratio of obstetric complications. 3

References

Guideline

Interpreting Thromboelastography (TEG) Parameters and Clinical Applications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Correcting Low Maximum Amplitude on Thromboelastography

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Value of thromboelastography in the assessment of platelet function.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.